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Purpose: To report the long-term results of intravitreal bevacizumab (Avastin) 
therapy for choroidal neovascularization (CNV) secondary to non-age-related macular 
degeneration (non-AMD).
Methods: This prospective interventional case series was conducted on patients with 
non-AMD CNV. All patients received 1.25 mg intravitreal bevacizumab and were 
followed for at least 18 weeks. Indications for retreatment were decreased visual 
acuity or recurrence of subretinal fluid or hemorrhage associated with leakage on 
fluorescein angiography. Primary outcome measures were changes in best-corrected 
visual acuity (BCVA) and central macular thickness (CMT). Secondary outcome 
measures consisted of any adverse event related to the therapy.
Results: The study included 31 eyes of 28 patients with non-AMD CNV including 
idiopathic (n=11), due to myopia (n=7), angioid streaks (n=5), and other disorders 
(n=8). Mean initial BCVA was 20/100 which improved to 20/60 at 6 weeks; 20/40 at 
12, 18, 24, and 36 weeks; and 20/30 at 54 weeks. Serial optical coherence tomography 
measurements showed mean CMT of 288 µm at baseline, which was decreased to 209 
µm at last visit (P=0.95). There was no correlation between the underlying disease 
and changes in BCVA during the follow-up period.
Conclusion: Intravitreal bevacizumab significantly improved visual acuity in eyes 
with non-AMD CNV due to various etiologies.
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INTRODUCTION
Choroidal neovascularization (CNV) may 
develop in the course of over 30 different ocular 
disorders.1,2 The most common cause of CNV 
apart from age-related macular degeneration 
(AMD) is pathologic myopia.3 In patients aged 
50 years or younger, CNV may develop in the 
absence of any identifiable cause and is considered 
to be idiopathic.3,4 Other less common causes 
of CNV include angioid streaks, central serous 
chorioretinopathy (CSC), ocular histoplasmosis 
syndrome (OHS), multifocal choroiditis, trauma, 
and hereditary eye diseases.3,5,6
A number of studies have demonstrated 
that the vascular endothelial growth factor 
(VEGF), a potent mitogen for endothelial cells, 
plays a principal role in the development of 
neovascularization in various chorioretinal 
diseases.7,8 There have been recent reports on IVB for Non-AMD CNV; Salehipour et al
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the use of intravitreal bevacizumab (IVB), a 
pan anti-VEGF antibody, for CNV secondary 
to high myopia,9-20 angioid streaks,21,22 CSC,23
idiopathic,23,24 OHS,25,26 and choroidal osteoma.27
However, limited information is available on 
the long-term effect of treatment with VEGF-
blocking agents on CNV secondary to non-
AMD causes. Herein we present the long-term 
outcomes of IVB therapy on non-AMD CNV 
due to various etiologies.
METHODS
This prospective interventional case series 
includes consecutive patients with non-AMD 
CNV who were recruited from the Department 
of Ophthalmology at Labbafinejad Medical 
Center, a tertiary referral eye care center in 
Tehran. Inclusion criteria were: clinical setting 
suggesting CNV of non-AMD origin, subfoveal 
or juxtafoveal location of the lesion and evidence 
of leakage on fluorescein angiography (FA). 
Exclusion criteria consisted of clinical features 
suggesting CNV secondary to AMD, diabetic 
retinopathy and glaucoma. However, patients 
who had previously received thermal laser 
therapy or photodynamic therapy (PDT) for 
CNV were not excluded. The Ethics Committee 
of the Ophthalmic Research Center approved the 
study protocol, and informed consent regarding 
the risks, benefits, and alternatives of therapy 
was obtained from all patients.
At baseline, all patients underwent 
a comprehensive examination, including 
determination of best-corrected visual acuity 
(BCVA), slitlamp biomicroscopy, intraocular 
pressure (IOP) measurement, dilated fundus 
examination, color fundus photography, 
fluorescein angiography (FA) and optical 
coherence tomography (OCT). BCVA was 
evaluated by certified optometrists using a 
Snellen chart at 6m with conversion to logMAR 
equivalent for statistical analysis. OCT was 
performed by a technician using the three 
dimensional OCT-1000 (Topcon, Europe Medical 
B.V., Capelle a/d IJssel, The Netherlands), and 
central macular thickness (CMT) was measured 
using the retinal thickness map.
The decision for IVB injection was made 
according to presence of active CNV judged 
by the presence of leakage on FA, and intra- 
or subretinal fluid on OCT. Intravitreal 
bevacizumab injection was performed as an 
outpatient procedure under aseptic conditions 
in the operating room. Topical anesthesia was 
achieved using 0.5% tetracaine drops, and 5% 
povidone-iodine solution was applied to the 
eyelids and the cul-de-sac, followed by draping 
and insertion of a lid speculum. Intravitreal 
injection of 1.25 mg/0.05 ml bevacizumab 
(Avastin, Roche, Basel, Switzerland) was 
performed using a 30-gauge needle 4-mm 
posterior to the limbus in the superior temporal 
quadrant. Topical ciprofloxacin (4 times a day) 
was prescribed for 3 days after the injection.
Patients were examined the day after the 
procedure and after 1, 6, 12, 18, 24, 36, and 54 
weeks. At each visit BCVA, a complete ocular 
examination and OCT were repeated; fundus 
photography and FA were performed as 
necessary. After initial treatment, the decision 
to retreat was based on clinical, OCT and 
angiographic findings. Subsequent injections 
were administered at least 6 weeks after a 
previous injection if the patients complained 
of decreased vision and/or increased 
metamorphopsia, or in cases which recurrence 
of intra- or subretinal fluid, or hemorrhage 
was associated with leakage on FA. Primary 
outcome measures were changes in BCVA 
and CMT based on OCT. Secondary outcome 
measures were any ocular or systemic adverse 
events during the study period.
Statistical analysis was performed using 
SPSS version 15.0 (SPSS Inc., Chicago, USA). 
Serial changes in BCVA and OCT were compared 
using paired t-test. Analysis of variance 
(ANOVA) was employed to compare changes in 
BCVA and the number of injections in relation 
to the underlying disease. P values less than 
0.05 were considered as statistically significant.
RESULTS
Thirty-one phakic eyes of 28 patients including 
10 male and 18 female subjects with mean age 
of 37.8±12.1 (range, 11-67) years were enrolled. 
Patients’ characteristics are shown in Table 1.IVB for Non-AMD CNV; Salehipour et al
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Underlying diagnoses associated with non-AMD 
CNV were idiopathic in 11 eyes, myopia in 
7 eyes, angioid streaks in 5 eyes, and other 
causes in 8 eyes (ocular toxoplasmosis in 3 
eyes, multifocal choroiditis in 2 eyes; and OHS, 
CSC and choroidal osteoma, each in 1 eye). 
Nine eyes had received 1 to 3 sessions of PDT 
3 to 6 months prior to IVB injection, and one 
eye had 2 sessions of thermal laser therapy 
previously. IVB was used as primary treatment 
in the remaining 21 eyes. Mean follow-up period 
was 40.4±12 (range, 18-54) weeks.
Visual results are shown in Table 2 and 
outcomes within each subgroup are detailed in 
Table 3. Figure 1 shows changes in mean BCVA 
during the study period. Mean BCVA at baseline 
was 0.69±0.51 logMAR (20/100) which improved 
to 0.44±0.39 logMAR (20/60, P=0.001) 6 weeks 
after initial IVB injection and remained stable at 
12 weeks (0.34±0.39 logMAR, 20/40, P<0.001), 
18 weeks (0.33±0.37 logMAR, 20/40, P<0.001), 
24 weeks (0.29±0.37 logMAR, 20/40, P<0.001), 
36 weeks (0.28±0.32, 20/40, P=0.001), and final 
follow-up (0.23±0.26 logMAR, 20/30, P=0.029). 
Only one eye experienced BCVA deterioration 
ŮNKPGHTQODCUGNKPGCVNCUVHQNNQYWR#V
week 54, 60% of eyes demonstrated visual 
KORTQXGOGPVŮNKPGUCPFRTGVTGCVOGPV
BCVA was preserved in the remaining 40% 
(Table 2). Changes in BCVA during the study 
Underlying
diagnosis
No. of
eyes
Mean age
(years)
Male/Female
Mean follow-up
(weeks)
Mean number of
injections
History of PDT or
thermal laser
(No. of eyes)
Idiopathic 11 32.7 2/7 37.6 2.6 2
Myopia 7 44.4 2/5 46.2 2 5
Angioid streaks 5 51.4 2/3 39.6 2.6 2
Toxoplasmosis 3 24.7 2/1 50 1
Multifocal choroiditis 2 30.3 Female 39.7 1.3
Ocular histoplasmosis 1 47 Male 48 2 1
CSC 1 31 Male 24 1
Choroidal osteoma 1 19 Female 30 2
Total 31 37.7 10/18 40.4 2.1 10
No, number; PDT, photodynamic therapy; CSC, central serous chorioretinopathy
Table 1. Clinical characteristics of patients enrolled in the study
Visual parameter Baseline 6 weeks 12 weeks 18 weeks 24 weeks 36 weeks 54 weeks
logMAR BCVA (Mean ± SD) 0.69±0.51 0.44±0.39 0.34±0.36 0.33±0.37 0.29±0.37 0.28±0.32 0.23±0.26
Mean Snellen BCVA 20/100 20/60 20/40 20/40 20/40 20/40 20/30
P-Value (compared to baseline) 0.001 <0.001 <0.001 <-0.001 0.001 0.029
$%8#EJCPIGUŮNKPG
Improved 44.0% 73.1% 63.6% 62.5% 63.2% 60.0%
Same 56.0% 23.1% 36.4% 37.5% 31.6% 40.0%
Worse 0.0% 3.8% 0.0% 0.0% 5.3% 0.0%
AMD, age-related macular degeneration; CVN, choroidal neovascularization; BCVA, best-corrected visual acuity; SD, standard 
deviation
Table 2. Visual results of bevacizumab injection for non-AMD CNV
Subgroup Baseline 6 weeks 12 weeks 18 weeks 24 weeks 36 weeks
Idiopathic 0.58±0.53
20/80
0.47±0.042
20/60
0.35±35
20/40
0.32±0.37
20/40
0.28±0.41
20/40
0.26±0.33
20/40
Myopia 1.07±0.55
20/240
0.44±0.22
20/60
0.57±0.33
20/70
0.79±0.27
20/120
0.52±0.45
20/70
0.40±0.34
20/50
Angioid Streaks 0.40±0.54
20/50
0.47±0.55
20/60
0.28±0.42
20/40
0.21±0.41
20/30
0.05±0.70
20/20
0.21±0.37
20/30
Others 0.72±0.22
20/100
0.36±0.44
20/50
0.20±0.33
20/30
0.17±0.17
20/30
0.20±0.28
20/30
0.33±0.21
20/40
Table 3. Snellen best corrected visual acuity (mean±SD) at baseline and after bevacizumab injection for subgroups of 
non-AMD CNVIVB for Non-AMD CNV; Salehipour et al
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period showed no significant relationship with 
the underlying condition (P=0.14 and P=0.15 
at 36 and 54 weeks, respectively). The mean 
number of intravitreal injections was 2.16 which 
also showed no correlation with the underlying 
disorder (P=0.19).
Figure 2 shows serial changes in mean 
CMT during the study period. Mean CMT 
Figure 1. Changes in best-corrected visual acuity (BCVA) 
following intravitreal bevacizumab for treatment 
of non-age-related macular degeneration choroidal 
neovascularization.
Figure 2. Changes in central macular thickness following 
intravitreal bevacizumab injection for treatment of 
non-age-related macular degeneration choroidal 
neovascularization.
Figure 3. Fundus photograph (A) of a patient with choroidal neovascularization (CNV) and subretinal hemorrhage 
secondary to ocular toxoplasmosis with best-corrected visual acuity (BCVA) of 20/100 at baseline; central macular 
thickness (CMT) was 357 µm on optical coherence tomography (OCT) (B). After 6 weeks, resolution of the subretinal 
hemorrhage is noted (C) with improvement of BCVA to 20/40; CMT is reduced to 276 µm (D).
A
B
C
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was 288 µm at baseline, decreased to 240 µm
after 6 weeks, and was further reduced to 209 
µm after 54 weeks. However, changes in CMT 
were not statistically significant (P= 0.95). 
Representative examples demonstrate the effect 
of IVB for treatment of CNV secondary to 
ocular toxoplasmosis (Fig. 3), CSC (Fig. 4), and 
angioid streaks (Fig. 5), and also for idiopathic 
CNV (Fig. 6).
None of the patients developed systemic 
(thromboembolic events or cerebral vascular 
accidents), or ocular (intraocular inflammation, 
IOP rise, cataract formation, endophthalmitis 
and retinal detachment) complications related 
to IVB injection.
DISCUSSION
In this prospective study, eyes treated with IVB 
for non-AMD CNV showed significant visual 
improvement which was maintained for about 
one year. The current work may support the 
notion that VEGF is a critical stimulus for CNV 
formation in different clinical settings such 
as myopia, angioid streaks, toxoplasmosis, 
multifocal choroiditis, choroidal osteoma and 
ocular histoplasmosis. Based on data from 
VJGNCUVHQNNQYWR$%8#KORTQXGFŮNKPGU
in 60% of IVB treated eyes. These functional 
results are in agreement with a previous case 
series of IVB for non-AMD CNV, including 
idiopathic CNV (improvement in 50% of cases 
at 3 months24 and 73% of eyes at 6 months23), 
and CNV secondary to CSC and punctate inner 
choroidopathy (improvement in 73% of eyes 
at 6 months)23 where similar criteria for visual 
improvement were applied.
Visual results in our patients compare 
favorably with the natural history and with 
outcomes of previous treatment modalities 
for non-AMD CNV. Previous studies have 
shown with observation alone and with 
Figure 4. Fundus photograph and optical coherence tomography (OCT) of the right eye of a patient with choroidal 
neovascularization (CNV) secondary to central serous chorioretinopathy before and 3 months after a single intravitreal 
bevacizumab (IVB) injection. Fundus photograph demonstrates a juxtafoveal CNV with retinal hemorrhage around 
the CNV (A), best-corrected visual acuity (BCVA) is 20/80. OCT shows macular thickening with intraretinal fluid and 
shallow pigment epithelial detachment (B). Fundus photograph (C) and OCT (D) three months after IVB demonstrate 
resolution of the hemorrhage with scarring while BCVA improved to 20/25.
A
B
C
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Figure 5. A 57-year-old woman with angioid streaks and prior history of photodynamic therapy, presented with 
metamorphopsia in the left eye while visual acuity decreased to 20/25. An extrafoveal choroidal neovascularization 
(CNV) with retinal hemorrhage and thickening was seen in the fundus (A). The angiogram shows leakage in 
association with the recurrent CNV (B). Three months after a single intravitreal bevacizumab (IVB) injection, resolution 
of thickening and hemorrhage is noted (C). Angiography 3 months after IVB demonstrates resolution of leakage (D),
visual acuity improved to 20/20 without metamorphopsia.
A C
B
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Figure 6. Fundus photography and optical coherence 
tomography (OCT) of the left eye of a patient with 
idiopathic choroidal neovascularization (CNV). A 
subfoveal CNV with subretinal fluid and retinal 
hemorrhage is noted (A), baseline best-corrected visual 
acuity (BCVA) was 20/200. OCT demonstrates severe 
subretinal fluid with cystic spaces, and central macular 
thickness (CMT) of 598 µm (B). After 6 months and 
2 intravitreal bevacizumab (IVB) injections marked 
improvement is evident (C) and OCT shows resolution 
of cystic spaces with mild neurosensory detachment and 
CMT of 302 µm (D). After 10 months, CMT reached 290 
µm (E). At final follow-up (after 13 months), the macula 
appeared normal, with a yellow subretinal spot (F),
and OCT shows absence of any intra- and sub-retinal 
fluid (G). CMT and BCVA were 248 µm and 20/30, 
respectively.
A
E
F
G
B
C
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PDT, 42%4 and 58%28 of eyes with idiopathic 
%08FGOQPUVTCVGŮNKPGUQHXKUWCNCEWKV[
improvement. In contrast, in the present study, 
75% of eyes in the subgroup with idiopathic CNV 
UJQYGFŮNKPGUQHKORTQXGOGPVHQNNQYKPI
IVB injections.
Patients with CNV secondary to pathologic 
myopia have a poor natural course;29 in a 
randomized trial, eyes treated with PDT did 
not fare better than untreated controls.30 The 
effectiveness of IVB for myopic CNV has 
been evaluated in multiple case series.9-20 In 
a prospective, noncomparative interventional 
cases series, Ruiz-Moreno et al17 reported the one 
year results of IVB for treatment of subfoveal 
CNV in highly myopic eyes. Twenty-nine eyes 
underwent 3 monthly injections of 1.25 mg IVB 
and were evaluated in terms of BCVA and OCT 
at baseline and then monthly for one year. FA 
was performed at baseline, after 3 months and 
whenever CNV activity was suspected; this 
was similar to our treatment and follow-up 
protocol. Of 29 eyes, 16 were naive for treatment 
but 13 eyes had been previously treated with 
multiple sessions of PDT. Six eyes required 
repeat injections. Mean BCVA at baseline was 
0.55 logMAR which improved to 0.38 logMAR 
at 1 year; CMT decreased significantly at month 
12 as compared to baseline. The one year 
results of IVB injections (2.5 mg) for myopic 
CNV were also evaluated in a recent study on 
eyes without earlier treatment.20 Significant 
visual improvement and CMT reduction was 
observed in this series with a mean number of 1.4 
injections within 12 months. The mean number 
of injections was 2 in our study with greater 
follow-up as compared to previous studies. Two 
other recent studies on IVB for myopic CNV 
have also demonstrated comparable results at 
one year.18,19
The visual prognosis of CNV secondary to 
angioid streaks is dismal; a group of untreated 
patients lost 6 lines of visual acuity in 18 
months.31 The results of treatment for CNV 
secondary to angioid streaks are poor with 
thermal laser and disappointing with PDT. The 
visual results after PDT vary widely; however, 
all studies show loss of VA, including 1-line 
loss at 1-year,32 4.9-line loss at 18 months33
and 3-line loss at 42 months.34 Therefore it 
might be inferred that PDT is not a good 
treatment modality for CNV secondary to 
angioid streaks.31,32,34 In contrast, IVB may 
lead to modest improvement or stabilization 
in vision and lesion size in such eyes.22,33,35,36
In the present study, none of the patients with 
angioid streaks lost VA until final follow-up; 
FGOQPUVTCVGFXKUWCNKORTQXGOGPVŮNKPGU
and 80% maintained their pre-injection VA.
Schadlu et al25 reported the results of IVB 
in eyes with CNV resulting from OHS. Of 28 
eyes, 20 (71%) experienced visual improvement, 
VA remained unchanged in 4 (14%) eyes, and 
4 eyes experienced a decrease in vision. Mean 
follow-up was 22 weeks with an average of 1.8 
intravitreal injections. Adan et al26 also reported 
a case of presumed ocular histoplasmosis 
which responded remarkably well to IVB. 
We had only one case of CNV secondary to 
presumed ocular histoplasmosis in our series. 
Marked visual improvement and resolution 
of metamorphopsia was noted in this patient 
after IVB injection.
The result of IVB in eyes with CNV 
secondary to multifocal choroiditis in our series 
were comparable to the report by Fine et al37
who noted improved vision in 5 of 6 eyes. 
Deterioration of VA occurred in one patient due 
to subfovel rip of the RPE. We have reported 
the results of treatment of CNV secondary to 
choroidal osteoma elsewhere.27
In our study, changes in VA and the 
number of injections were not correlated with 
the underlying conditions which is consistent 
with the report by Chang et al.38
In summary, the results of this prospective 
study suggest that anatomical and visual 
outcomes of IVB treatment for non-AMD 
CNV are favorable. Limitations of the study 
include the small number of cases and lack of 
a control group. However, the low prevalence 
of certain underlying conditions may prevent 
performing large, randomized, controlled trials 
similar to those conducted for CNV secondary 
to AMD. In addition, it would unethical to 
withhold treatment from patients with non-
AMD CNV when the natural course of the 
condition is poor.IVB for Non-AMD CNV; Salehipour et al
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